Brian R. Curtis

Brian R. Curtis

Auto-generated profile, based on publicly available information

Brian R. Curtis

Platelet & Neutrophil Immunology Laboratory, Blood Research Institute, Versiti, Milwaukee, WI (B.R.C.).

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2009 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
IIIsbt Working Party On Granulocyte Immunobiology
Isbt Working Party On Granulocyte Immunobiology
PBP. Bierling
P. Bierling
JBJ. Bux
J. Bux
BCB. Curtis
B. Curtis
BFB. Flesch
B. Flesch
BZB. Zupanska
B. Zupanska
Background  Transfusion‐related acute lung injury (TRALI) is currently one of the most common causes of transfusion‐related major morbidity and death. Among the many TRALI mediators, leucocyte antibodies have been identified as important triggers of severe TRALI.Study Design and Methods  These recommendations were compiled by experts of the ISBT Working Party on Granulocyte Immunobiology, based on the results obtained in eight international granulocyte immunology workshops, their personal experiences and on published study results.Results  Leucocyte antibody screening has to include the detection of human leucocyte antigen (HLA) class I, class II and human neutrophil alloantigen antibodies using established and validated techniques. HLA class I antibody detection should be restricted to antibodies clinically relevant for TRALI. To avoid unnecessary workload, TRALI diagnosis should be assessed by consultation with the reporting clinician and thorough exclusion of transfusion‐associated circulatory overload/cardiac insufficiency. In patients diagnosed with TRALI having donors with detectable leucocyte antibodies, evidence of leucocyte incompatibility should be provided by either cross‐matching or typing of patient for cognate antigen.Conclusion  Leucocyte antibody screening for the immunological clarification of TRALI cases as well as for identification of potentially alloimmunized blood donors is feasible and can be performed in a reasonable and quality assured manner. This practice can contribute to the prevention of antibody‐mediated TRALI.

1 December 2019 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
JHJaleah Hawkins
Jaleah Hawkins
RARichard H Aster
Richard H Aster
BCBrian R Curtis
Brian R Curtis
Post transfusion purpura (PTP) is an uncommonly reported post transfusion adverse event that can present with severe thrombocytopenia; sometimes resulting in significant bleeding and hemorrhage. Its diagnosis can be elusive given its substantial symptomatic overlap with other thrombocytopenic syndromes. Underdiagnosis and underreporting make the true incidence of disease difficult to define. While clinical suspicion is key, laboratory evidence of platelet-targeted antibodies and identification of the antigen(s) they recognize are necessary to confirm the diagnosis. A curious aspect of PTP is paradoxical destruction of both transfused and autologous platelets. Although the first case was reported over 50 years ago, this aspect of PTP pathogenesis is still not fully understood and is widely debated. Several theories exist, but conclusive evidence to support most is lacking. Despite limited understanding of disease incidence and etiology, treatment with IVIG (Intravenous Immunoglobulin) has become standard practice and can be highly effective. Although recurrence is rare, precautions should be taken if patients with a history of PTP require transfusions in the future.

25 February 2021 in Blood
Verified
Journal Article
Open access
PDF file
BBBethany Samuelson Bannow
Bethany Samuelson Bannow
DWDeepti M. Warad
Deepti M. Warad
CJCurtis G. Jones
Curtis G. Jones
SPShannon M. Pechauer
Shannon M. Pechauer
BCBrian R. Curtis
Brian R. Curtis
APAnand Padmanabhan
Anand Padmanabhan
Heparin-induced thrombocytopenia (HIT) is a life-threatening, prothrombotic, antibody-mediated disorder. To maximize the likelihood of recovery, early and accurate diagnosis is critical. Widely available HIT assays, such as the platelet factor 4 (PF4) heparin enzyme-linked immunosorbent assay (ELISA) lack specificity, and the gold-standard carbon 14–labeled serotonin release assay (SRA) is of limited value for early patient management because it is available only through reference laboratories. Recent studies have demonstrated that pathogenic HIT antibodies selectively activate PF4-treated platelets and that a technically simpler assay, the PF4-dependent P-selectin expression assay (PEA), may provide an option for rapid and conclusive results. Based upon predefined criteria that combined 4Ts scores and HIT ELISA results, 409 consecutive adults suspected of having HIT were classified as disease positive, negative, or indeterminate. Patients deemed HIT indeterminate were considered disease negative in the primary analysis and disease positive in a sensitivity analysis. The ability of PEA and SRA to identify patients judged to have HIT was compared using receiver operating characteristic curve statistics. Using these predefined criteria, the diagnostic accuracy of PEA was high (area under the curve [AUC], 0.94; 95% confidence interval [CI], 0.87-1.0) and similar to that of SRA (AUC, 0.91; 95% CI, 0.82-1.0). In sensitivity analysis, the AUCs of PEA and SRA were also similar at 0.88 (95% CI, 0.78-0.98) and 0.86 (95% CI, 0.77-0.96), respectively. The PEA, a technically simple nonradioactive assay that uses ∼20-fold fewer platelets compared with the SRA, had high accuracy for diagnosing HIT. Widespread use of the PEA may facilitate timely and more effective management of patients with suspected HIT.

28 November 2019 in Blood
Verified
Journal Article
Open access
PDF file
NZNanyan Zhang
Nanyan Zhang
SSSentot Santoso
Sentot Santoso
RARichard H. Aster
Richard H. Aster
BCBrian R. Curtis
Brian R. Curtis
PNPeter J. Newman
Peter J. Newman
Key Points: HPA allele–specific HLA class I–negative MKs can be differentiated from CRISPR-edited human iPSCs. Such cells can be stored frozen and thawed to use in whole-cell flow cytometric assays to detect anti-HPA-3a, -3b, and -9b alloantibodies.

21 September 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
PPPriyanka Pandey
Priyanka Pandey
NZNanyan Zhang
Nanyan Zhang
BCBrian R. Curtis
Brian R. Curtis
PNPeter J. Newman
Peter J. Newman
GDGregory A. Denomme
Gregory A. Denomme
Despite the recent advancements in transfusion medicine, red blood cell (RBC) alloimmunization remains a challenge for multiparous women and chronically transfused patients. At times, diagnostic laboratories depend on difficult‐to‐procure rare reagent RBCs for the identification of different alloantibodies in such subjects. We have addressed this issue by developing erythroblasts with custom phenotypes (Rh null, GPB null and Kx null/Kell low) using CRISPR/Cas9 gene‐editing of a human induced pluripotent stem cell (hiPSC) parent line (OT1‐1) for the blood group system genes: RHAG, GYPB and XK. Guide RNAs were cloned into Cas9‐puromycin expression vector and transfected into OT1‐1. Genotyping was performed to select puromycin‐resistant hiPSC KOs. CRISPR/Cas9 gene‐editing resulted in the successful generation of three KO lines, RHAG KO, GYPB KO and XK KO. The OT1‐1 cell line, as well as the three KO hiPSC lines, were differentiated into CD34+CD41+CD235ab+ hematopoietic progenitor cells (HPCs) and subsequently to erythroblasts. Native OT1‐1 erythroblasts were positive for the expression of Rh, MNS, Kell and H blood group systems. Differentiation of RHAG KO, GYPB KO and XK KO resulted in the formation of Rh null, GPB null and Kx null/Kell low erythroblasts, respectively. OT1‐1 as well as the three KO erythroblasts remained positive for RBC markers—CD71 and BAND3. Erythroblasts were mostly at the polychromatic/ orthochromatic stage of differentiation. Up to ~400‐fold increase in erythroblasts derived from HPCs was observed. The availability of custom erythroblasts generated from CRISPR/Cas9 gene‐edited hiPSC should be a useful addition to the tools currently used for the detection of clinically important red cell alloantibodies.

10 April 2023 in Transfusion
Verified
Journal Article
Closed access
ZCZachary A. Colvin
Zachary A. Colvin
JSJennifer Schiller
Jennifer Schiller
STShirng‐Wern Tsaih
Shirng‐Wern Tsaih
RSRuchika Sharma
Ruchika Sharma
RGRachael Grace
Rachael Grace
BCBrian R. Curtis
Brian R. Curtis